Effect of metformin on the high-density lipoprotein proteome in youth with type 1 diabetes.
cholesterol efflux
high‐density lipoprotein
metformin
proteomics
type 1 diabetes
Journal
Endocrinology, diabetes & metabolism
ISSN: 2398-9238
Titre abrégé: Endocrinol Diabetes Metab
Pays: England
ID NLM: 101732442
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
12
11
2020
revised:
21
04
2021
accepted:
23
04
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
15
3
2022
Statut:
epublish
Résumé
Youth with type 1 diabetes (T1D) have normal or elevated High-Density Lipoprotein Cholesterol (HDL-C), however, the function of HDL, partly mediated by the HDL proteome, may be impaired. Metformin can be used as an adjunct therapy in youth with T1D, but its effects on the HDL proteome are unknown. To determine the effect of metformin on the HDL proteome. Youth (12-20 years old) with T1D who had a BMI > 90th percentile, HbA1c > 8.0% and Tanner stage 5. Double-blinded, placebo-controlled randomized sub-study. We examined the effects of metformin ( The relative abundance of 84 HDL-associated proteins were measured. Two proteins were significantly affected by metformin treatment, peptidoglycan recognition protein 2 (PGRP2; +23.4%, Despite having little effect on HDL-C, metformin increased PGRP2 and A2MG protein on HDL in youth with T1D, but had no significant effect on CEC. Further studies are needed to understand the impact of PGRP2 and A2MG on other HDL functions.
Sections du résumé
BACKGROUND
BACKGROUND
Youth with type 1 diabetes (T1D) have normal or elevated High-Density Lipoprotein Cholesterol (HDL-C), however, the function of HDL, partly mediated by the HDL proteome, may be impaired. Metformin can be used as an adjunct therapy in youth with T1D, but its effects on the HDL proteome are unknown.
OBJECTIVE
OBJECTIVE
To determine the effect of metformin on the HDL proteome.
SUBJECTS
METHODS
Youth (12-20 years old) with T1D who had a BMI > 90th percentile, HbA1c > 8.0% and Tanner stage 5.
METHODS
METHODS
Double-blinded, placebo-controlled randomized sub-study. We examined the effects of metformin (
RESULTS
RESULTS
The relative abundance of 84 HDL-associated proteins were measured. Two proteins were significantly affected by metformin treatment, peptidoglycan recognition protein 2 (PGRP2; +23.4%,
CONCLUSIONS
CONCLUSIONS
Despite having little effect on HDL-C, metformin increased PGRP2 and A2MG protein on HDL in youth with T1D, but had no significant effect on CEC. Further studies are needed to understand the impact of PGRP2 and A2MG on other HDL functions.
Identifiants
pubmed: 34277985
doi: 10.1002/edm2.261
pii: EDM2261
pmc: PMC8279605
doi:
Substances chimiques
Cholesterol, HDL
0
Lipoproteins, HDL
0
Proteome
0
Metformin
9100L32L2N
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00261Subventions
Organisme : NHLBI NIH HHS
ID : K24 HL145076
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001432
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK116073
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001409
Pays : United States
Organisme : NHLBI NIH HHS
ID : K22 HL141299
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Informations de copyright
© 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Authors have nothing to disclose.
Références
Atherosclerosis. 2010 Jan;208(1):3-9
pubmed: 19595353
World J Gastroenterol. 2006 Oct 28;12(40):6429-39
pubmed: 17072974
Mol Cell Proteomics. 2007 Sep;6(9):1638-55
pubmed: 17533153
PLoS One. 2019 Jun 27;14(6):e0218533
pubmed: 31246976
Health Qual Life Outcomes. 2006 Oct 11;4:80
pubmed: 17034640
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
N Engl J Med. 2015 May 7;372(19):1871-2
pubmed: 25946297
J Proteome Res. 2010 Oct 1;9(10):5239-49
pubmed: 20718489
Nat Rev Immunol. 2011 Nov 11;11(12):837-51
pubmed: 22076558
J Biol Chem. 1984 Oct 10;259(19):12201-9
pubmed: 6434538
J Lipid Res. 2020 Mar;61(3):306-315
pubmed: 31953305
Mol Cell Proteomics. 2015 Dec;14(12):3247-57
pubmed: 26483418
Lipids Health Dis. 2017 Oct 30;16(1):207
pubmed: 29084567
Genome Biol. 2006;7(8):232
pubmed: 16930467
Atherosclerosis. 2012 Sep;224(1):218-21
pubmed: 22858285
Biochim Biophys Acta. 2012 Mar;1821(3):405-15
pubmed: 21840418
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3265-3278
pubmed: 30938764
N Engl J Med. 2011 Jan 13;364(2):127-35
pubmed: 21226578
Atherosclerosis. 2017 Apr;259:104-113
pubmed: 28242049
Cardiovasc Diabetol. 2018 Dec 19;17(1):158
pubmed: 30567548
Atherosclerosis. 2018 Nov;278:278-285
pubmed: 30347343
J Proteome Res. 2008 Sep;7(9):3661-7
pubmed: 18700793
JAMA. 2015 Dec 1;314(21):2241-50
pubmed: 26624824
Nature. 2015 Dec 10;528(7581):262-266
pubmed: 26633628
J Lipid Res. 2008 Feb;49(2):481-90
pubmed: 18025001
Cardiovasc Diabetol. 2019 Mar 28;18(1):43
pubmed: 30922315
Pediatr Diabetes. 2016 Jun;17(4):257-65
pubmed: 26080650
Clin Proteomics. 2018 Mar 6;15:10
pubmed: 29527140
Circ Res. 2017 Mar 31;120(7):1183-1196
pubmed: 28360349
Circulation. 2018 Dec 18;138(25):2895-2907
pubmed: 30566007
J Lipid Res. 1980 Mar;21(3):284-91
pubmed: 7381323
Curr Diab Rep. 2017 Nov 3;17(12):134
pubmed: 29101482
Circulation. 2014 Oct 21;130(17):1532-58
pubmed: 25170098
Nat Med. 2017 Jul;23(7):850-858
pubmed: 28530702
Arterioscler Thromb Vasc Biol. 2018 Dec;38(12):2827-2842
pubmed: 30571168
J Am Coll Cardiol. 2016 May 17;67(19):2310-2312
pubmed: 27173041
J Lipid Res. 2005 Oct;46(10):2246-53
pubmed: 16061948
J Lipid Res. 1982 Aug;23(6):936-40
pubmed: 6813413
Atherosclerosis. 2009 Oct;206(2):434-8
pubmed: 19376519